Literature DB >> 6192080

Non-specific normal immunosuppressive protein (Nip): purification and further biochemical characterization.

R Gavison-Goren, D Nelken.   

Abstract

The non-specific normal immunosuppressive protein (Nip) has been described in our laboratory and its biological activity was extensively studied. In the present study, further purification analyses of Nip were conducted. Fractionation of Nip by Ultrogel AcA 34 column resulted in peak (I) that displayed Nip activity in that it exhibited marked inhibition of in-vitro blastogenic responses of human lymphocytes to mitogenic stimulation, in vitro it inhibited EL4 tumour-cell proliferation. Partial dissociation of Ultrogel peak I on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) resulted chiefly in three bands: one of high molecular weight, which is considered to be the carrier, an intermediate band of 50,000-60,000 (under non-reducing conditions) and a band of high mobility and low molecular weight approximately 6,000-14,000. Further fractionation of peak I on Sepharose-6B in 6 M guanidine-HCl resulted in two main peaks. The biological activity resided in the second peak, which corresponded to the low molecular weight fraction of 6,000-14,000. Nip is suggested to be a complex molecule comprised of a low molecular weight peptide or glycopeptide, which displays the biological activity, and a macromolecular glycoprotein carrier, which conserves its stability.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192080      PMCID: PMC1454309     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Isolation of an immunosuppressive peptide fraction from human plasma.

Authors:  J C Occhino; A H Glasgow; S R Cooperband; J A Mannick; K Schmid
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

2.  Immunoregulatory d-globulin: failure to inhibit antibody response when administered after antigen exposure.

Authors:  A H Glasgow; J O Menzoian; S R Cooperband; R B Nimberg; K Schmid; J A Mannick
Journal:  J Immunol       Date:  1973-07       Impact factor: 5.422

3.  Inhibition of PHA-induced lymphocyte stimulation by the pregnancy zone protein.

Authors:  B Von Schoultz; T Stigbrand; A Tärnvik
Journal:  FEBS Lett       Date:  1973-12-15       Impact factor: 4.124

4.  The effect of immunoregulatory globulin (IRA) upon lymphocytes in vitro.

Authors:  S R Cooperband; A M Badger; R C Davis; K Schmid; J A Mannick
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

5.  Effect of human chorionic somatomammotrophin and human chorionic gonadotrophin on phytohaemagglutinin-induced lymphocyte transformation.

Authors:  S F Contractor; H Davies
Journal:  Nat New Biol       Date:  1973-06-27

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Inhibition of graft-versus-host reaction by preincubation of the graft with a thymic extract (lymphocyte chalone).

Authors:  N Kiger; I Florentin; G Mathé
Journal:  Transplantation       Date:  1973-11       Impact factor: 4.939

8.  Production by stimulated macrophages of factors depressing lymphocyte transformation.

Authors:  D S Nelson
Journal:  Nature       Date:  1973-11-30       Impact factor: 49.962

9.  Effect of Normal Immunosuppressive Protein (NIP) on tumor growth in mice.

Authors:  H Ovadia; N Hanna; D Nelken
Journal:  Eur J Cancer       Date:  1975-06       Impact factor: 9.162

10.  Activation of T and B lymphocytes in vitro. II. Biological and biochemical properties of an allogeneic effect factor (AEF) active in triggering specific B lymphocytes.

Authors:  D Armerding; D H Katz
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

View more
  1 in total

1.  Role of a SER immune suppressor in immune surveillance.

Authors:  S K Oh; S Ross; J Walker; S Zeisel
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.